{"id":269272,"date":"2026-09-25T09:08:08","date_gmt":"2026-09-25T03:38:08","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=269272"},"modified":"2026-09-25T09:08:08","modified_gmt":"2026-09-25T03:38:08","slug":"shilpa-medicare-share-price-238-percent-rally-earnings-test","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/shilpa-medicare-share-price-238-percent-rally-earnings-test\/","title":{"rendered":"Shilpa Medicare’s 238% Rally Now Faces a Real Earnings Test"},"content":{"rendered":"

Shilpa Medicare share price up 238% in 2026. Q1FY27 revenue up 43% YoY to Rs 469 crore. PAT up 115% to Rs 101 crore, aided by a one-time tax reversal. EBITDA margin steady at 30%.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The Shilpa Medicare share price has surged 238 percent in 2026, and the stock’s fourth consecutive record quarter is now putting that rally to a genuine test. Q1FY27 consolidated revenue rose 43 percent year-on-year to Rs 469 crore, with EBITDA up 42 percent to Rs 139 crore and profit after tax jumping 115 percent to Rs 101 crore, though part of that profit surge came from a one-time deferred tax reversal of roughly Rs 26.84 crore. With formulations, biologics and CDMO all scaling alongside the core API business, the real question for investors is whether this pipeline can keep converting into sustained earnings growth.<\/p>\n<\/div>\n

Shilpa Medicare has been one of the standout pharmaceutical stories of 2026, and its latest quarterly results give investors a genuine data point to test whether the rally has been backed by real operational improvement or simply riding sector-wide sentiment.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n